DUBLIN–(BUSINESS WIRE)–The “Lung injury Market by Therapy, Injury Type, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.
The global lung injury market was valued at $1,579.47 million in 2020, and is projected to reach $2,417.41 million by 2030 registering a CAGR of 4.20% from 2021 to 2030.
Lung injury is a disorder of acute inflammation that causes disruption of the lung endothelial and epithelial barriers. Often it becomes a life-threatening condition caused by severe acute hypoxemic respiratory failure. In addition, it is a key reason of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a significant impact on public health, with high incidence rate across the world. Moreover, it requires administration of rapid and goal-oriented therapy to prevent further lung damage.
The growth of the global lung injury market is majorly driven by rise in prevalence of lung-related diseases and increase in geriatric population. Furthermore, increase in awareness related to treatment of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is expected to notably contribute toward the growth of the global market. However, complications associated with the use of therapies and low adoption rate due to these complications hinder the market growth. On the contrary, pipeline drugs for the treatment of acute lung injury are being studied in late phase of clinical trials. These drugs are likely to be available in the market in next few years, which is expected to offer remunerative opportunity for the expansion of the market during the forecast period.
The global lung injury market is segmented into therapy, injury type, end user, and region. Depending on therapy, the market is bifurcated into medication and devices. The medication segment is further categorized into pharmacotherapy, fluid management, and inhaled nitric oxide. Moreover, the devices is subdivided into mechanical ventilation and adjunctive procedures devices. On the basis of injury type, the market is segregated into direct injury and indirect injury. By end user, it is fragmented into hospitals & clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits
- The study provides an in-depth analysis of the global lung injury market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps understand the applications and products of lung injury used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Market Dynamics
Drivers
- Rise in prevalence of lung-related diseases
- Surge in geriatric population
- Increase in adoption of new technologies with availability of high number of drugs used in lung injury treatment
- Recent advancements in research related to treatment of acute lung injury
Restraint
- High cost of therapies coupled with lack of established treatment
Opportunity
- New developments in therapies
Companies Mentioned
- Apeptico Forschung Und Entwicklung GmBH
- Bayer AG
- General Electric Company
- Glaxosmithkline Plc,
- Koninklijke Philips N.V.
- Linde Plc.
- Medtronic Plc.
- Ony Biotech Inc
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/jmwp4f
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900